272 related articles for article (PubMed ID: 21955669)
1. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.
Voon V; Schoerling A; Wenzel S; Ekanayake V; Reiff J; Trenkwalder C; Sixel-Döring F
BMC Neurol; 2011 Sep; 11():117. PubMed ID: 21955669
[TBL] [Abstract][Full Text] [Related]
2. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
Cornelius JR; Tippmann-Peikert M; Slocumb NL; Frerichs CF; Silber MH
Sleep; 2010 Jan; 33(1):81-7. PubMed ID: 20120624
[TBL] [Abstract][Full Text] [Related]
3. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome.
Schreglmann SR; Gantenbein AR; Eisele G; Baumann CR
Parkinsonism Relat Disord; 2012 Feb; 18(2):207-9. PubMed ID: 22030321
[TBL] [Abstract][Full Text] [Related]
4. Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study.
Marques A; Figorilli M; Pereira B; Derost P; Debilly B; Beudin P; Vidal T; Durif F; Fantini ML
Sleep Med; 2018 Aug; 48():148-154. PubMed ID: 29913341
[TBL] [Abstract][Full Text] [Related]
5. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
Pourcher E; Rémillard S; Cohen H
J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
[TBL] [Abstract][Full Text] [Related]
6. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
Bayard S; Langenier MC; Dauvilliers Y
Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
[TBL] [Abstract][Full Text] [Related]
7. Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.
Hankin C; Lee D; Garcia-Borreguero D; Wang Z
J Clin Sleep Med; 2019 Sep; 15(9):1225-1232. PubMed ID: 31538593
[TBL] [Abstract][Full Text] [Related]
8. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study.
Vela L; Martínez Castrillo JC; García Ruiz P; Gasca-Salas C; Macías Macías Y; Pérez Fernández E; Ybot I; Lopez Valdés E; Kurtis MM; Posada Rodriguez IJ; Mata M; Ruiz Huete C; Eimil M; Borrue C; Del Val J; López-Manzanares L; Rojo Sebastian A; Marasescu R
J Neurol Sci; 2016 Sep; 368():150-4. PubMed ID: 27538621
[TBL] [Abstract][Full Text] [Related]
9. [Impulsive-compulsive syndrome in Parkinson's disease].
Nikitina AV; Fedorova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
[TBL] [Abstract][Full Text] [Related]
10. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
Bayard S; Cochen De Cock V; Dauvillers Y
Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of impulsive-compulsive behaviors in early Parkinson's disease: a prospective study.
Marković V; Stanković I; Petrović I; Stojković T; Dragašević-Mišković N; Radovanović S; Svetel M; Stefanova E; Kostić V
J Neurol; 2020 Apr; 267(4):1127-1136. PubMed ID: 31902006
[TBL] [Abstract][Full Text] [Related]
12. Dopamine Agonists and Impulse Control Disorders: A Complex Association.
Grall-Bronnec M; Victorri-Vigneau C; Donnio Y; Leboucher J; Rousselet M; Thiabaud E; Zreika N; Derkinderen P; Challet-Bouju G
Drug Saf; 2018 Jan; 41(1):19-75. PubMed ID: 28861870
[TBL] [Abstract][Full Text] [Related]
13. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
[TBL] [Abstract][Full Text] [Related]
14. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors.
De Sousa SMC; Baranoff J; Rushworth RL; Butler J; Sorbello J; Vorster J; Thompson T; McCormack AI; Inder WJ; Torpy DJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31580439
[TBL] [Abstract][Full Text] [Related]
15. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?
Heim B; Djamshidian A; Heidbreder A; Stefani A; Zamarian L; Pertl MT; Brandauer E; Delazer M; Seppi K; Poewe W; Högl B
Neurology; 2016 Jul; 87(1):36-40. PubMed ID: 27261093
[TBL] [Abstract][Full Text] [Related]
16. Clinical spectrum of impulse control disorders in Parkinson's disease.
Weintraub D; David AS; Evans AH; Grant JE; Stacy M
Mov Disord; 2015 Feb; 30(2):121-7. PubMed ID: 25370355
[TBL] [Abstract][Full Text] [Related]
17. Impulse control disorders in Parkinson's disease: a retrospective analysis of 1824 patients in a 12-year period.
Gunduz A; Çiftçi T; Erbil AC; Senoglu G; Ser MH; Apaydın H
Neurol Sci; 2024 Jan; 45(1):171-175. PubMed ID: 37581771
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease-related disorders in the impulsive-compulsive spectrum.
Wolters ECh; van der Werf YD; van den Heuvel OA
J Neurol; 2008 Sep; 255 Suppl 5():48-56. PubMed ID: 18787882
[TBL] [Abstract][Full Text] [Related]
19. Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease.
Merola A; Romagnolo A; Rizzi L; Rizzone MG; Zibetti M; Lanotte M; Mandybur G; Duker AP; Espay AJ; Lopiano L
J Neurol; 2017 Jan; 264(1):40-48. PubMed ID: 27761641
[TBL] [Abstract][Full Text] [Related]
20. Impulse control disorders in Parkinson's disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges.
Bhattacharjee S
Neurol India; 2018; 66(4):967-975. PubMed ID: 30038082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
